GENE ONLINE|News &
Opinion
Blog

2021-10-08| Special

Landmark CRISPR Trial Shows Promise Against Fighting Blindness, but Is It a Cure?

by Isha Kapoor
Share To
Cambridge, MA-based, leading genome editing biotech company, Editas Medicine, recently announced encouraging clinical data in the world's first attempt to use the CRISPR gene editing tool to treat blindness.

Preliminary results from the open-label Phase1/2 BRILLIANCE clinical trial of its investigational CRISPR-based experimental medicine, EDIT-101, have rekindled hope for the patients suffering from blindness due to Leber congenital amaurosis 10 (LCA10).

The safety and efficacy assessments were presented at the XIXth International Symposium on Retinal Degeneration (RD2021) on September 29th.

GO Prime with only $1.49 now

LATEST
35% Of Better Therapeutics’ Staff to be Cut to Extend the Company’s Runway
2023-03-27
Pharming’s Joenja Racks Up FDA Approval For Rare Primary Immunodeficiency
2023-03-27
Ways to Reduce Carbon Emission in Cement Manufacturing
2023-03-26
Moderna Injects $76 Million To Kickstart Lipid Nanoparticle Delivery Partnership With Generation Bio
2023-03-24
Shining a Light on Oncology with Rakuten Medical Co-CEO Takashi Toraishi
2023-03-23
Incyte’s Zynyz Secures FDA Approval for Treating a Rare and Aggressive Skin Cancer
2023-03-23
Biohaven Licenses TYK2/JAK1 Dual Inhibitor From China’s Highlight In $970 Million Pact
2023-03-23
Scroll to Top